Correspondence 0001178913-24-000513 from Entera Bio Ltd. (ENTX)
Entera Bio Ltd.
Date: Feb. 14, 2024 · CIK: 0001638097 · Accession: 0001178913-24-000513
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276844
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Attention: Doris Stacey Gama Entera Bio Ltd. (the “Company”) Registration Statement on Form S-3, as amended (the “Registration Statement”) Filed February 2, 2024 File No. 333-276844
Dear Ms. Gama
The Company hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of effectiveness of the Registration Statement so that such Registration Statement will become effective as of 4:15 p.m. on February 14, 2024, or as soon thereafter as practicable.
Very truly yours,
Entera Bio Ltd.
Show Raw Text
CORRESP
1
filename1.htm
Entera Bio Ltd.
Minrav Building – Fifth Floor
Jerusalem, Israel 9112002
February 14, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
Attention: Doris Stacey Gama
RE:
Entera Bio Ltd. (the “Company”)
Registration Statement on Form S-3, as amended (the “Registration Statement”)
Filed February 2, 2024
File No. 333-276844
Dear Ms. Gama
The Company hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended,
acceleration of effectiveness of the Registration Statement so that such Registration Statement will become effective as of 4:15 p.m. on February 14, 2024, or as soon thereafter as practicable.
Very truly yours,
Entera Bio Ltd.
By:
/s/ Miranda Toledano
Name: Miranda Toledano
Title: Chief Executive Officer